Three BiTEs set to disrupt r/r multiple myeloma space with $9 billion sales by 2030
Recent developments in the field of bispecific T-cell engagers (BiTEs) have led to the approval of three therapies for relapsed/recurrent multiple myeloma (RRMM).
These are: Pfizer’s (NYSE: PFE) Elrexfio (elranatamab); and Tecvayli (teclistamab) and Talvey (talquetamab) both developed by Johnson & Johnson (NYSE: JNJ).
Clinical data of the three have been surprising, surpassing previously anticipated response rates. With an ever-growing number of patients entering the RRMM population, these BiTEs are poised to become the pre-eminent therapeutic option, recording sales of nearly $9 billion by 2030, according to pharma analytics company GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze